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Abstract  
Introduction: Anterior and posterior segment eye diseases are highly challenging to 
treat, due to the barrier properties and relative inaccessibility of the ocular tissues. 
Topical eye drops and systemically delivered treatments result in low bioavailability. 
Alternatively, direct injection of medication into the ocular tissues is clinically 
employed to overcome the barrier properties, but injections cause significant tissue 
damage and are associated with a number of untoward side effects and poor patient 
compliance. Microneedles (MNs) has been recently introduced as a minimally 
invasive means for localizing drug formulation within the target ocular tissues with 
greater precision and accuracy than the hypodermic needles.  
Areas covered: This review article seeks to provide an overview of a range of 
challenges that are often faced to achieve efficient ocular drug levels within targeted 
tissue(s) of the eye. It also describes the problems encountered using conventional 
hypodermic needle-based ocular injections for anterior and posterior segment drug 
delivery. It discusses research carried out in the field of MNs, to date. 
Expert opinion: MNs can aid in localization of drug delivery systems within the 
selected ocular tissue. And, hold the potential to revolutionize the way drug 
formulations are administered to the eye. However, the current limitations and 
challenges of MNs application warrant further research in this field to enable its 
widespread clinical application.  
Keywords: Ocular drug delivery, Posterior segment, Anterior segment, Microneedle, 
Minimally-invasive 
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Article highlights box  
• Visual impairment and blindness are potentially the most devastating health 
problem worldwide. 
• Drug delivery to the eye is challenging due to the extremely delicate nature, 
relative inaccessibility, and barrier properties of ocular tissues 
• Topical and systemic routes of ocular drug delivery result in low or sub-
therapeutic drug levels; drug delivery implants need surgical implantation.  
• Injections into the eye using conventional hypodermic can provide direct 
access to the target tissues. However, this method is highly invasive and 
causes considerable discomfort, pain and associated with a number of side 
effects 
• Microneedles (MNs) could offer minimally-invasive means of ocular drug 
delivery, less tissue trauma, less drug dosage and precise localisation of the 
medication. 
• MNs allow precise injections within the thin ocular tissues (e.g. sclera and 
cornea) – an advantage for localized drug delivery 
• MNs when integrated with sustain drug delivery formulations can offer long-
term localised drug delivery in treating both anterior and posterior segment 
eye diseases.  
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1. Introduction   
Visual impairment and blindness are potentially the most devastating health problem 
worldwide. The World Health Organization (WHO) estimates that globally about 285 
million people are visually impaired of which 39 million are blind, and 246 have a 
low vision [1]. Ocular diseases can be broadly classified into anterior and posterior 
segment diseases. Anterior segment diseases that can cause serious vision impairment 
or discomfort include corneal neovascularization (CNZ), glaucoma, bacterial/fungal 
keratitis, uveitis, herpes simplex keratitis, blepharitis and dry eye syndrome. 
Additionally, diseases that originate in the posterior segment of the eye lead to 
permanent loss of vision, if left untreated, and account for the majority of blindness, 
such as in age-related macular degeneration (AMD), diabetic retinopathy, diabetic 
macular edema, cytomegalovirus retinitis, and other chorioretinal diseases [2].  
In general, conditions that affect the anterior chamber are less likely to be sight 
threatening compared to those that affect the posterior segment. Nevertheless, drug 
delivery to the eye can be challenging, owing to the extremely delicate nature of the 
ocular tissues concerned, their relative inaccessibility, and barrier properties of ocular 
tissues [3,4], which hinders efficient drug diffusion to target tissues. For example, 
posterior segment of the eye, which includes the retina, choroid, and vitreous body, is 
difficult to access due to the recessed location within the orbital cavity.  
To date, multiple approaches have been used to deliver drugs to the eye such as 
systemic, topical, periocular (or transscleral) and intravitreal routes. Topical (e.g. eye 
drops) and systemic (e.g. oral tablets) routes result in low or sub-therapeutic drug 
levels due to multiple ocular barriers, requiring administration of unnecessarily high 
concentrations of drug that causes drug-related toxicity and producing low treatment 
efficacy [5]. To overcome the barrier function of the eye and to enhance localization 
of the drug close to the target tissues, injections are given either directly into the eye 
(intravitreal injection, IVT), around the outer surface of the eye (periocular or 
transscleral route) or within the tissues (intracorneal and intrascleral). These injections 
are given using conventional hypodermic needles. Although periocular route is 
considered to be less invasive than the IVT, transient diffusion of a drug across the 
sclera is limited. Drug diffusion across the scleral membrane is dependent upon 
drug’s solubility, molecular weight/molecular radius, charge and polarity [6]. 
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However, this method has shown low intraocular bioavailability due to a delay in 
diffusion through the sclera, systemic clearance and loss of drug before reaching the 
target tissues (e.g. retina) [7]. One of the standard treatments to overcome limitations 
of periocular injections is either an IVT, for posterior segment diseases, or 
intracorneal injections, for anterior segment diseases.  
Using conventional hypodermic needles for intraocular injections is known to causes 
considerable discomfort, pain and requires a specialized set of skills. Notably, 
traditional injections given on frequent basis and over long-term may increase the 
chances of severe ocular complications and poor patient compliance. Therefore, there 
is a high demand for less invasive technologies that not only enhance patient 
compliance but also allow localised and precise drug delivery to the eye. In this 
regard, application of minimally-invasive microneedles (MNs) for ocular drug 
delivery is a relatively new concept. To date, only limited work has been done in this 
area. Therefore, this review article seeks to provide an overview of  - typical 
challenges that are often faced to achieve efficient ocular drug levels within targeted 
tissue(s) of the eye; problems encountered using conventional hypodermic needle-
based ocular injections; and how minimally-invasive MNs could assist in overcoming 
these challenges in treating sight-threatening eye diseases. It also provides an 
overview of the limitations and difficulties of MNs application to the eye and its 
prospects. Furthermore, to the author’s knowledge, this is the first review of MNs 
application for ocular drug delivery, which is aimed to benefit researchers in this field.     
2. Challenges and Obstacles of Ocular Drug Delivery  
Although eye offers a convenient site for drug administration for various conditions, 
there are many challenges. Drug delivery research has significantly increased for 
other routes such as oral and transdermal routes, whereas progress in the area of 
ocular drug delivery has been gradual and relatively limited. Lee and Robinson in 
1986 described the majority of ocular drug delivery systems as ‘primitive and 
inefficient’ [9], referring mainly to solutions, suspensions, and ointments. In 1995 
around 90% of the ophthalmic formulations on the market were based on these three 
systems [10]. This statement can still be employed to describe a large number of 
systems currently used for the treatment of ocular conditions, although substantial 
advances have been made to enable targeting of ocular tissues in recent years, and 
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more sophisticated treatment strategies are currently under development [5, 11]. 
Many researchers attest to the difficulties of effective and efficient drug delivery to 
the eye, primarily due to the range of ocular barriers that are crucial in maintaining 
healthy physiological function but pose a variety of challenges for drug delivery. 
Following sections briefly, discuss the challenges faced and need for invasive 
procedures to overcome the barrier function of ocular tissues. 
2.1 Anterior Barriers  
In the anterior segment of the eye, the first challenge to drug delivery is the 
precorneal lacrimal fluid. Lacrimal fluid turnover and clearance is approx. 1 µL/min 
[12] via the nasolacrimal duct. Therefore, formulations instilled to the eye are cleared 
from the ocular surface in a matter of minutes [13]. Additionally, the lacrimal fluid is 
rich in peptides and proteins, which are capable of binding drug molecules and 
inhibiting their release or permeation [14].  
The next barrier encountered in the anterior segment is the cornea. The cornea is the 
clear, outer layer of the eyeball, with dual action of limiting the entry of exogenous 
substances into the eye and protecting the ocular tissue. This tissue in an adult human 
has an average dimension of 11.5 mm horizontally, 10.5 mm vertically with an mean 
surface area of 1.3 cm2, representing around 7% of the total surface area of an eyeball. 
The thickness in the central region is around 0.52 mm and increases towards the 
periphery [15]. Cornea is a multi-layered tissue composed of five distinct layers; from 
anterior to posterior they are the epithelium, Bowman’s layer, stroma, Descemet’s 
membrane, and endothelium, which affect the transport of drug molecules into the eye. 
The epithelium layer with an approximately of 50 µm in thickness consists of 5-7 
layers of superficial, wing and basal epithelial cells. This layer forms a significant 
barrier to topical ophthalmic formulations, especially for hydrophilic and 
macromolecular drugs due to the barriers lipoidal nature and the tight junctions 
between the cells, importantly in the superficial epithelium cells [17,18]. Drug 
molecules require a partition coefficient of greater than 1 to adequately permeate the 
epithelium [19]. The molecular weight of hydrophilic molecules also plays a major 
factor in their permeation through the corneal epithelium [20] with those larger than 
60-100 Da being unable to pass [20, 21].  
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The stroma is the second layer and accounts for >90% of the cornea thickness with an 
approximate thickness of 500 µm. It mainly consists of an extracellular matrix, 
stromal cells, and approximately 4% glycosaminoglycans [22]. Water-soluble 
molecules readily traverse this layer, and even high molecular weight drugs diffuse 
with ease [17, 23]. However, it restricts the movement of lipophilic drugs and 
macromolecules with a molecular weight of > 50,000 Da [24]. The endothelium layer 
consists of a monolayer of cuboidal cells with an approximate thickness of 5 µm [16]. 
Both the epithelium and the endothelium are hydrophobic in nature, providing a 
barrier to the movement of hydrophilic molecules across the cornea. However, the 
endothelium is approximately 2.7 times more permeable than the epithelium [25].  
The thin, semi-transparent mucous membrane of the conjunctiva provides another 
challenge to anterior drug delivery. The vast presence of localised blood capillaries 
and rich lymphatic system within the conjunctiva, result in the rapid clearance of drug 
molecules. This significant drug loss into the systemic circulation has the issue of not 
only lowering the ocular bioavailability but can lead to unwanted systemic exposure 
of the drug [26]. 
2.2 Posterior Barriers  
The posterior segment of the eye contains its own array of barriers such as sclera, 
choroid, and blood-retinal barrier (BRB), resulting in numerous challenges to drug 
delivery.  
Scleral tissue offers mechanical support and strength to the eye. It covers 
approximately 80% of the eyeball surface and forms relatively a large surface area 
16.3 cm2 [27]. It is an elastic, tough, vascular, opaque white-yellow and microporous 
tissue composed of collagen and elastin fibres entwined with proteoglycans [28]. 
Scleral thickness varies throughout its circumference. In humans, the mean scleral 
thickness is reported to be 0.53 mm, with the thickness portion being approximately 1 
mm at the posterior, near the optic nerve, and the thinnest portion being 0.39 mm at 
the equator [27]. Sclera consists of four layers they are from outer side to the inner 
side: Tenon`s capsule, episclera, stroma and lamina fusca [15]. Besides not having 
epithelium and endothelium layers, the scleral tissue differs primarily from the 
corneal tissue in the uniformity of the arrangement of the collagen fibres and the 
degree of hydration [29]. Relative to the cornea, the sclera has irregular collagen 
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fibres and a 4-fold lower concentration of proteoglycans resulting in lower water 
content, i.e., 68% in comparison to 78% in the corneal stroma [29]. Besides, the sclera 
is perforated by blood vessels and has an extensive nerve supply [29]. Due to the 
sclera’s high aqueous content, hydrophilic molecules can diffuse through this layer 
more readily than hydrophobic molecules. The sclera is permeable to high molecular 
weight compounds and even proteins of 150 kDa [30], however, permeability declines 
exponentially with increase in the molecular radius [31]. The charge of the drug 
molecule also presents a challenge to penetration through the sclera; for example, 
positively charged molecules are at risk of interacting with the negatively charged 
proteoglycans within the sclera [28]. 
The choroid is one of the most highly vascularised regions of the body, and its 
primary function is to supply blood, rich in oxygen and nutrients, to the retina [32]. 
Bruch’s membrane, located between the choroid and the retinal pigment epithelium 
(RPE), also functions as a barrier to the movement of vessels from the choroid into 
the RPE and retina. With increased aging the choroid has been shown to thin [33,34].  
In contrast, Bruch’s membrane thickens with increasing age, causing a disruption of 
its barrier activity, giving rise to some ocular diseases [35]. Changes in thickness 
within the choroid and Bruch’s membrane can affect successful drug permeation and 
penetration from subconjunctiva and sclera, resulting in decreased drug delivery to 
the retina [32].                     
The BRB acts to restrict entry of unwanted molecules from choroid into the retina. It 
is the most significant barrier to systemic drug delivery. Following systemic 
administration drug molecules can enter the highly vascularized choroid relatively 
easily, but are commonly unable to pass the BRB. The BRB is extremely efficient in 
performing this restricting function due to its unique composition. The outer portion is 
formed by the retinal pigment epithelium (RPE), and the inner portion of the barrier is 
formed by the tight junctions of retinal capillary endothelial cells [13,36]. 
The retina is the intended site of action for most drugs delivered to the posterior 
segment of the eye. It does not have its own barrier function but can present 
challenges to drug delivery. The inner limiting membrane, which separates the retina 
and the vitreous humour, is composed of 10 distinct extracellular matrix proteins and 
is thought to prevent the penetration of some drug molecules into the retina [32]. 
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However, it has been shown that anti-vascular endothelial growth factors (VEGF) 
such as bevacizumab (Avastin®, Genentech Inc.) with a molecular weight of 149 kDa, 
can successfully penetrate into the RPE via IVT route [37].  
3. Ocular injections to overcome barrier functions 
Regarding ocular drug delivery, the choice of route of administration or type of 
delivery system is very much dictated by the target tissue and potential barriers that 
need to overcome. Table 1 summarises different routes of ocular drug delivery along 
with their benefits and challenges. As can be appreciated from the information 
provided in Table 1, each route and method of administration have its advantages and 
disadvantages. However, this review is primarily focused on minimally-invasive 
means of ocular drug delivery using MNs. Hence, we will discuss challenges that are 
faced using highly-invasive conventional hypodermic injections in delivering drugs to 
the eye (Fig. 1). Hypodermic needle-based injections are clinically employed to gain 
direct access to the target tissues to overcome barrier function of the eye, in treating a 
number of diseases.     
3.1 Anterior segment injections  
Topical administration of eye drops has ery low ocular bioavailability (< 5%). 
Therefore, frequent drops are necessary, yet it is only effective in treating diseases of 
the front of the eye. Whereas, due to biological barriers, the systemic administration 
has to be given at very high doses which cause systemic toxicity.   
 
Therapies used to treat diseases of the anterior segment of the eye have been widely 
researched and are well documented. Formulation approaches for treating anterior eye 
diseases include eye drops, gels, suspensions, and emulsions, to name a few. However, 
the most commonly formulated preparation is topical eye drops that have the 
advantage of being non-invasive and can be easily self-administered, resulting in 
good patient compliance. Nevertheless, topical administration is inefficient due to the 
barrier properties of corneal epithelium, thus requiring either frequent administration 
of medication or high doses – especially in treating certain corneal conditions such as 
CNZ, dystrophy, fungal and bacterial keratitis, which may lead to vision impairment 
or loss if not treated effectively [38]. As a result, direct injections of medication are 
commonly practised in treating these conditions such as subconjunctival, intrastromal, 
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intracameral, or intracorneal injections (Fig. 1). These injections enable achieving 
high drug concentrations within the specific tissue of the anterior segment of the eye, 
and found to be particularly beneficial in the emergency management of acute 
conditions (e.g. CNZ and fungal keratitis).  
In subconjunctival injections, selected medication is directly delivered in 
subconjunctival space (Fig. 1). It is considered to be most patient friendly than any 
other types of ocular injections. Most commonly hypodermic needles of sizes ranging 
from 21-30G are used for subconjunctival injections, with injections volumes of up to 
0.1 ml. For example, in treating CNZ, bevacizumab (Avastin®) was administered by 
topical route, at a concentration of 2.5 mg/ml eye drop (10 µL) given 5-times per day 
[39], but higher concentration (4, 5 or 10 mg/ ml) eye drops were given only 2-times 
per day. Here, a frequ nt administration is required due to poor penetration of the 
bevacizumab, which is a high molecular weight (149kDa) hydrophilic drug. 
Alternatively, to lower drug concentrations and reduce the frequency of 
administration, subconjunctival injections were given at 1.25 mg or 2.5mg/0.1 ml 
with lower frequencies [40-42]; this demonstrates advantages of injections over 
topical delivery. Although subconjunctival injections guarantee better delivery than 
topical eye drops, local side effects – such as hemorrhage, have been reported [43]. 
Additionally, rapid drug elimination following subconjunctival administration is also 
well documented, which results in drainage of formulation into systemic circulation 
thereby lowering ocular bioavailability [44]. The short residence time limits the 
effective permeation of drug molecules through multiple ocular barriers before 
reaching their intended site of action at either back or front of the eye. 
Alternatively, intrastromal, intracameral, or intracorneal injections allow direct 
administration of the medication within the target tissue. For example, intrastromal 
injections (Fig. 2) have been widely used as a mean of effecient drug delivery 
especially in the management of CNZ [43,45] and fungal keratitis [43,46]. For 
example, using a 31G needle intrastromal injection of bevacizumab, approx. 10 µL 
(100 µg), was performed in human eyes. In certain cases, multiple intrastromal 
injections were given in the same eye [43], so as to accommodate a higher amount of 
drug per eye. In another study, patients who were unresponsive to topical antifungal 
therapy, targeted delivery of voriconazole was achieved by intrastromal injections (50 
µg/0.1 mL using 30G needle), which was found to be effective to treat deep 
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recalcitrant fungal keratitis. Five divided doses (i.e., five intrastromal injections) were 
given around the infiltrate to form a deposit of the drug around the circumference of 
the lesion to ensure the formation of a barrage of intrastromal voriconazole around the 
entire infiltrate, to enhance the efficacy of voriconazole [47]. Although, intrastromal 
injection using a hypodermic needle have shown promising results [45,46], it is 
unpleasant for patients; it is associated with series of ocular complications and side 
effects including being painful and highly-invasive; possibility of imposing bacterial 
infections; inflammation and tissue damage; and requires expertise in clinical 
administration [48,49]. More importantly, delivering precise volumes of drug 
solutions/suspensions, often < 10-25 µL, within the thin corneal tissue of 0.52 mm 
thickness is technically challenging and highly impossible to produce reproducible 
results in each patient. Thus, varying dosages will lead to different levels of 
therapeutic efficacy among the patients. 
3.2 Posterior segment Injections  
Delivery of drug molecules, to treat visually impairing ocular conditions that originate 
in the posterior segment of the eye, has been the most challenging task to the 
pharmaceutical scientists and retinal specialists. Patient-friendly administration routes 
such as oral and topical dosage forms provide ineffective drug delivery to the 
posterior segment; thus direct injections in the eye, IVTs (Fig. 1), were found to be 
effective. In fact, IVTs have become the ‘gold standard’ to allow localised delivery of 
drugs to the back of the eye, with millions of injections given each year for patients 
suffering from a range of eye diseases worldwide.  
IVTs were first utilised in 1911 to introduce air into the eye to repair retinal 
detachment [51]. Since then, their use has evolved as a method of repairing ocular 
ailments and delivering a range of therapeutics for the treatment of numerous ocular 
conditions, especially those of the posterior segment. Over the last number of decades, 
the use of IVTs has risen considerably; with these injections being one of the most 
frequently performed medical procedures in the US [52]. It is also estimated that in 
the UK in a department with around 500,000 patients in their care, 50-100 of these 
injections are performed weekly [53]. IVTs allow localised delivery of therapeutics 
and therefore reducing any systemic adverse effects [54]. According to the Royal 
College of Ophthalmologists guidelines on IVTs, the needles used should be 30G 
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needles non-colloidal clear solutions and 27G for particulate preparations. The 
injection needle length should be 12 to 15mm i.e. 1/2 to 5/8 inch, with a maximum 
injection volume of 100 µL [55].  
Although IVTs are not overly patient-friendly, they are capable of overcoming 
multiple ocular barriers and deliver adequate drug concentrations almost directly to 
the site of action [56]. Nevertheless, IVT being invasive method is associated with 
multiple adverse effects and complications – e.g. raised intraocular pressure (IOP), 
discomfort or pain (despite the use of anesthesia), intraocular inflammation, retinal 
detachment, haemorrhage, endophthalmitis, cataract, lens damage and potentially 
blindness [4,57,58]. All of these issues require supplementary medication. In treating 
chronic ocular diseases such as AMD, repeated injections, every 4-6 weeks, are 
required, indefinitely. Frequent injections will significantly increase the burden on 
patients and physicians. Furthermore, intravitreal delivery with conventional 
hypodermic needles should strictly adhere to numerous safeguards to avoid 
mechanical injury to the lens and retina [59]. These risks are dependent upon the 
needle type, where lower gauge needles cause more pain and higher damage to the 
eye. Therefore, smaller needles, 27 to 30 G, are preferable.  
Drug formulations can also be injected on the outer surface of the eyeball, through 
periocular injections (transscleral delivery) such as sub-tenon, retrobulbar, peribulbar 
and posterior juxtascleral (Fig. 1), which are considered to be less invasive than IVT. 
Transscleral delivery via periocular administration is thought to be one of the safest 
means of achieving stable drug concentrations within the vitreous and retina, although 
there have been reports of anterior segment complications after periocular injection 
such as raised IOP, cataract, and strabismus. Other challenges to drug delivery via the 
transscleral are dependent on the nature of the drug molecule. Interestingly, the sclera 
is highly permeable to large drug molecules; however the RPE is a significant barrier 
to diffusion for both these macromolecules and hydrophilic drug molecules, it may be 
the rate-limiting feature in the delivery of these molecules via the transsceleal route to 
the retina [60]. While molecular weight isn’t a major factor in drug delivery via the 
transscleral route, molecular radius of the drug molecule is. It has been shown that a 
smaller molecular radius will result in increased permeability through the scleral 
tissue [30].  
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Conventional hypodermic injections are capable of delivering drug formulations to 
the target site, but numerous adverse effects and risks associated with conventional 
injections are still a major problem. Although tremendous research interest in 
developing novel sustained release formulation is ongoing, so as to maintain constant 
drug levels at the target ocular tissues for prolonged periods and reduce the frequency 
of injections – technologies that enable safe delivery of the existing or new sustained 
release formulations are still limited. Therefore, in an attempt to overcome highly 
invasive ocular injections using standard hypodermic needles, and safer delivery of 
medication minimally-invasive MNs devices was found to be of significant interest.  
4. Minimally-invasive MNs for ocular drug delivery  
MN is an attractive technology that offers minimally-invasive drug delivery. MNs 
have been extensively investigated over the last 15 years to enhance transdermal drug 
delivery and therapeutic drug monitoring [62-64]. MNs are typically 25–2000 µm in 
height and have been fabricated from a wide range of materials and in different 
shapes. For further information, readers can refer to our MN book for details about 
methods of MN fabrication and its application in transdermal drug delivery [65]. The 
materials that have been most commonly used in the fabrication of MNs are silicon, 
steel, glass or polymer to form either solid and hollow type MNs. The painless 
application of MNs has significantly increased research interest in the MNs 
application for drug delivery, therapeutic monitoring and cosmeceutical applications. 
Consequently, benefits of MN application to the eye could offer several advantages 
over invasive intraocular injections that utilize long conventional hypodermic needles. 
The MNs are long enough to overcome the ocular barriers with potential advantages 
including – bypassing ocular barrier function (e.g. epithelium and sclera); allowing 
localised delivery of drug molecules within the ocular tissue (e.g. intrascleral and 
intrastromal delivery); minimizing pain, tissue damage and reduce the risk of 
infection; increase patient compliance due to nearly invisible needles, and the 
potential of providing a localized drug depot to achieve target drug delivery to the eye. 
 
In general, the transdermal application of MNs can be achieved via one of the 
following strategies in order to deliver therapeutics [66] (Fig. 3):  
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• A ‘poke with patch’ strategy that involves the application of a solid MN arrays to 
create micropores and further removal of arrays followed by the administration of 
a drug formulation – as a patch, a gel or a solution. Movement of molecules 
through microchannels occurs via passive diffusion thereby providing enhanced 
drug delivery.  
• A ‘coat and poke’ strategy that relies on coating a drug formulation onto the MNs 
and subsequent insertion of the coated MN array into the tissue. The drug is 
deposited within the tissue by the dissolution of the coating.   
• The third mode of drug delivery via MNs utilizes incorporation of drug 
molecules into the structure of polymeric MNs and subsequent insertion into the 
skin. The drug delivery depends on the rate of polymer dissolution or degradation 
within the skin.  
• Drug molecules can also be transported across the tissue via injection through 
hollow MNs, which is similar to the application of hypodermic needles [67].  
• Swelling MNs fabricated using polymers have been developed more recently. 
Following insertion into the skin, MNs imbibe tissue fluid and allow drug 
diffusion from a drug reservoir through the swollen polymeric matrix of the 
MNs [62].  
In reality, using MNs for drug delivery to the eye is a fairly new concept since very 
little research has been carried out in this field. To date, in enhancing ocular drug 
delivery using MNs, only three of the above five strategies of MN application have 
been investigated namely coated, soluble and hollow MNs. Primarily these three 
modes of MN application allow instant delivery and retrieval of the MNs (or its 
baseplate), which imitate the administration of conventional hypodermic needles to 
the eye. Literature indicates the use of either single solid or hollow MNs for ocular 
delivery of drug molecules of various molecular weights including sustain release 
nanoparticles, microparticles or depot forming gels – where the MNs were fabricated 
using silicon, stainless steel or glass.  
Prausnitz and co-workers were first to demonstrate the application of coated MNs to 
the eye [49]. In this study, Jiang et al. 2007 reported drug delivery into the anterior 
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segment of the eye using coated MNs (Fig. 4a). Individual stainless steel MNs 
measuring 500-750 µm in length and 200 x 50 µm in width, and 55° in tip angle were 
tested for anterior and posterior drug delivery via either intrascleral or intracorneal 
routes, respectively. MN was coated with model drug sodium fluorescein (approx. 
280 ng) and inserted halfway into the cornea of a rabbit eye and left in place for 2 
mins and then retrieved back. After 1 min following MN insertion, a sharp increase of 
intraocular fluorescein concentration and then gradually further increase peaked at 3 
hrs and then gradually decreased to background within 24 hrs. This study showed that 
the drug depot was formed within the cornea, which steadily released fluorescein into 
the anterior segment for hours. Although a small abrasion was noted at the site of MN 
insertion, it disappeared after 3 hrs. The study showed MN was able to achieve a 60-
fold increase in fluorescein in comparison to topical application. In this study, 
experiments were also performed using pilocarpine-coated MN, which showed a 45-
fold increase in its bioavailability relative to topical administration. Jiang et al. 2007 
used the same individual stainless steel MN coated with model drugs i.e. 
sulforhodamine, protein, and DNA to be delivered to the posterior segment of the eye. 
The study revealed that MN penetrated in the human cadaver sclera to a depth of 300 
µm. The drug coating rapidly dissolved off the needles within the scleral tissue within 
20 sec after insertion. 
In another study, Jiang et al. 2008 demonstrated intrascleral delivery using a hollow 
glass MN not only for a simple model drug (sulforhodamine), but also 
micro/nanoparticles formulations [68]. The MN was fabricated from a borosilicate 
cylindrical glass micropipette tubes with 1.5 mm outer diameter and 0.86 mm internal 
diameter (Fig. 4b). Needles were initially inserted into the tissue at a depth of 700-
1080 µm, and retracted out of the tissue in increments of 60 µm during the solution 
injection. Sulforhodamine solution was then infused at a pressure of 15 psi. No 
solution was delivered into the tissue after the initial insertion. Upon further retraction 
from 200 to 300 µm, the delivery was achieved at volumes of 10 to 35 µL of fluids 
containing either soluble drug molecule sulforhodamine B or nanoparticles 
suspensions from an individual MN. However, microparticles were only delivered in 
the presence of hyaluronidase and collagenase spreading enzymes. The enzymes in 
this case were used to breakdown the tissue components so as to accommodate the 
microparticles.  
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Unlike intrastromal or intrascleral injection using MNs, Patel et al. 2011 [69] 
investigated posterior drug delivery in suprachoroidal space (SCS) using hollow MN. 
The SCS is a potential space between the sclera and choroid that goes 
circumferentially around the eye. Being immediately adjacent to the choroid and 
retina, delivery in SCS can offer targeted drug delivery to these tissues. As like above, 
a single glass hollow MN measuring 800-1000 µm in length were used to infuse 
nanoparticle and microparticle suspensions into the SCS in ex vivo rabbit, pig and 
human eyeballs. MNs were shown to deliver sulforhodamine B as well as 
nanoparticle and microparticle suspensions into the SCS of rabbit, pig, and human 
eyes. Volumes up to 35 µL were administered consistently. The study suggested that 
particles of 20 and 100 nm could spread within the sclera as well as the SCS, whereas 
particles of 500 and 1000 nm localised exclusively in the suprachoroidal space (Fig. 
4c). To deliver 500 - 1000 nm particles in the SCS, a minimum MN length of 1000 
µm and a pressure of 250–300 kPa were necessary. Similarly, Patel et al. 2012 [70] 
used metal MNs fabricated from 33G needle cannulas, with 750 µm in length and the 
bevel at the orifice, to evaluate ocular pharmacokinetics of different molecules 
(sodium fluorescein, fluorescein isothiocyanate dextrans of 40 kDa and 250 kDa, and 
bevacizumab tagged with Alexa-Fluor 488) and particles (FluoSpheres) injected into 
the SCS of the rabbit eye. Here, the metal MNs were attached to a 1-mL syringe. In 
general, the molecules were cleared from the SCS within 1 day; therefore, particles 
were injected into the SCS so that the drug can be localized and remain for months. 
Particles of 20 nm to 10 µm diameter were injected into the SCS of rabbit eyes, in 
vivo, which remained within the SCS and choroid for at least 2 months. It was noted 
that the capillary drainage might play a role in clearance from the SCS. Nevertheless, 
this study demonstrated the ability to localize particles with in the SCS for sustaining 
drug delivery.  
In a recent in vivo study, Gilger et al. 2013 used the above 33G hollow MNs, 850 µm 
in height, to deliver triamcinolone acetonide (TA) to the SCS [71]. The study have 
demonstrated that 0.2 mg and 2.0 mg of the SCS TA was as effective in reducing 
inflammation as 2.0 mg of TA by IVT in a model of acute posterior uveitis 
inflammation. Furthermore, there was no evidence of adverse effect – i.e. increase in 
IOP, drug toxicity, or hemorrhage following MN application. Likewise, Chiang et al. 
2016 recently have investigated the circumferential distribution of particles in the 
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SCS of rabbit and human cadaver eyes [72]. Same hollow MNs were used as reported 
by [69] i.e. a 33G needle with 750µm height. A 200 nm diameter red-fluorescent 
microspheres with injection volumes ranging from 50 - 200 µL were performed in the 
SCS. In rabbit eyes, particles when injected in the superior or inferior hemispheres did 
not significantly cross into the other hemisphere, due to a barrier formed by the long 
posterior ciliary artery. In human eyes, the short posterior ciliary arteries prevented 
circumferential spread towards the macula and optic nerve. Therefore, suggesting that 
the anatomical barriers could hinder even spread of the administered drug or 
formulation within the SCS. Therefore the judicious selection of a region for injection 
is essential.  
Kim et al. 2014 [60] investigated using single solid stainless steel MN measuring 400 
µm in length coated with bevacizumab to treat CNZ. Results revealed that drug was 
delivered intrastromally and allowed dramatic dose sparing compared with 
subconjunctival and topical eye drops – providing just 4.4 µg of the drug needed to 
produce similar effect as much as 2,500 µg via subconjunctival injection and 52,500 
µg when delivered via eye drops.  
Song et al. 2015 [73] designed MN-based pen type device (Fig. 4d) to enhance the 
reliability of MN insertion, so as to allow easy insertion into a small target region of 
ocular tissue. A solid SU-8 resin based MN was fabricated and attached to a macro-
scale applicator to create the MN pen. The resulting MN had the base area of 200 × 
200 µm2 with the height of 140 µm. Rhodamine B, evans blue or sunitinib malate was 
used, along with polymer carrier, as a model drugs to dip coat the MN. It was shown 
that the MN pen enabled precise localization of drug within the stromal membrane of 
cornea, which is otherwise difficult to achieve when given topically due to corneal 
epithelium.  
Matthaei et al. 2012 [74], to improve reproducibility of injection method using hand-
held syringes, compared different type of hollow MNs and syringes and quantified the 
intrastromal distribution of Indian ink in mouse cornea by injections of different 
volumes (1 and 2 µL). Needles types and syringes tested were namely 33 G (attached 
to a 2.5 µL syringe), 35 G needles (attached to a 10 µL syringe) and glass MNs 
beveled to 25° and an inner tip diameter of approximately 50 µm (attached to a 2.5 µL 
syringe), respectively. Injections of 1 µL and 2 µL resulted in an overall mean of 49% 
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and 73% respectively of total corneal area involved.  The use of 33 G metal needles 
provided the most reliable and effective outcomes, whereas the glass MN tips broke 
within the stroma in 25% of cases which is undesirable and create potential safety 
concerns. Irrespective of needle type, a small amount of leakage was noted in all 
cases [74].  
Unlike the single HMNs or coated MNs, Palakurthi et al. 2011 [74] investigated MNs 
that were fabricated into an array of 3x3 biodegradable methotrexate loaded MNs 
with 2 mm in length, 2 mm in width, and 2.3 mm in height. The MNs were surgically 
placed in the deep lamellar scleral pocket in rabbit eye, in vivo, were found to be safe. 
The fundamental advantage of using MNs is its ability for painless or minimally-
invasive nature due to its micron-sized dimensions. However, in this study the term 
microneedle perhaps needs reconsideration, as the MNs were surgically implanted 
and were much higher in dimensions than those employed in both ocular and 
transdermal application.   
Long-acting ocular drug delivery systems such as micro-/nano-particles, liposomes, in 
situ implant forming gels and preformed solid implants are gaining tremendous 
interest due to their ability in maintaining constant drug levels following single 
administration [75]. However, administration of these formulations by either using 
standard hypodermic needles or surgical implantation would still hamper patient 
compliance. For example, some studies have previously developed and evaluated the 
administration of sustained release preformed intrascleral implants [76-79], as show 
in Fig 5 a and b. Although these intrascleral implants showed sustained drug release, 
they necessitate surgical administration within the thin tissue of sclera, which would 
have concerns greater than that seen with IVT injections. Additionally, any surgical 
procedure will only impose further costs and technical challenges with the treatment 
modality. We have recently demonstrated minimally invasive means of administering 
implants within the scleral tissue using HMNs [67]. In this study, we have shown 
administration of in situ implant forming thermoresponsive poloxamer-based gels into 
the scleral tissue to provide sustained drug delivery. HMN devices of 400, 500 and 
600 µm in height were fabricated from hypodermic needles (i.e. 27, 29 and 30 G) and 
tested for depth of penetration into rabbit sclera. We have seen sustained release of 
fluorescein sodium over 24 h which varied with the depth of gel delivery in the sclera. 
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In fact, upon HMN injection the gel turned into a semi-solid implant and effectively 
encapsulated within the sclera to form an intrascleral implant, as seen in the Fig. 5c. 
Such methods of implant formation, without the need for surgical intervention, would 
aid or enhance patient acceptability, and at the same time overcome a number of side 
effects that are commonly seen with surgical administration.   
5. Conclusion  
Ocular drug delivery is gaining significant interest among academia and 
pharmaceutical industry. However, the barrier function of the eye remains a 
significant challenge for successful anterior and posterior segment drug delivery. 
Currently, management of sight-threatening eye diseases requires frequent injections 
of medication either within the ocular tissues (intrastromal/intrascleral) or directly 
into the eyeball (IVT) using conventional hypodermic needles. Nevertheless, frequent 
administration of medication using hypodermic needles is associated with numerous 
side effects and has poor patient compliance. Therefore, application of minimally-
invasive MNs could offer numerous advantages to overcome the current issues 
surrounding hypodermic injections, as demonstrated by a number of studies in the 
past few years, which are discussed in this review. The advancing nature of research 
into MN delivery systems shows continual improvement in the ocular delivery of 
therapeutics. Moreover, Clearside Biomedical Inc. has recently demonstrated 
advantages of ocular drug delivery, in the SCS, using hollow MNs, which is currently 
in clinical trials (Phase 1/2) [80]. Although at its early stage, a number of parameters 
in relation to MN application to the eye warrants further investigation; for example, 
optimum MN design; volumes of injections vs. forces of application; safety, 
precision, accuracy and reproducibility; and manufacturing costs. Finally, MNs has 
significant potential to offer combined benefit of being minimally-invasive in 
application and ability to provide sustained localised drug delivery, which will 
provide significant benefits in overcoming current challenges faced by frequent 
intraocular injections using hypodermic needles.  
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6. Expert Opinion 
Ocular drug delivery is notoriously difficult and unfortunately many conditions of the 
eye, if not treated effectively, can cause visual impairment or blindness. Treating eye 
diseases is challenging, owing to the extremely delicate nature and recessed location 
of the ocular tissues. Conventional routes such as topical eye drops or systemic route 
of drug delivery yield suboptimal drug levels with the target ocular tissue. Thus 
frequent administration is practiced, which is associated with exposure to 
unnecessarily high drug concentrations that in turn causes systemic local drug-
induced toxicity and drug wastage.  
To address the issues associated with conventional administration, direct injection of 
drug formulations to the target tissue using conventional hypodermic needles is 
sought to be highly effective and, therefore, widely employed in clinical treatment of 
a number of ocular conditions such as CNZ, fungal keratitis, AMD, DM and DME. 
Direct injection at the disease site offers potential advantages such as overcoming 
ocular barrier function, the requirement of less amount of drug, instant delivery at the 
site of action and timely therapeutic benefits. Nevertheless, the long hypodermic 
needles are associated with a number of issues such as increase in IOP, retinal 
detachment, discomfort and pain, haemorrhage, likelihood of infections (e.g. 
endophthalmitis), and need for experienced personnel to administer the injections. 
Besides, precise anterior segment injections in cornea and sclera, often less than 1000 
µm in thickness, using long hypodermic needles is extremely challenging. Use of 
hypodermic needles is associated with higher degree of tissue trauma.    
To overcome both technical and clinical challenges associated with hypodermic 
needle-based injections, a less invasive mode of treatment is highly desirable. In this 
regard, researchers found that the use of MN for ocular applications to be an excellent 
alternative. It is importantly due to the fact that the MNs have successfully 
demonstrated not just enhanced transdermal drug delivery for the past 10-15 years 
[65], but also demonstrated its ability to cause significantly less pain [81] and has, 
therefore, ability to enhance patient compliance [82]. Therefore, translating the 
benefits of minimally-invasive MNs for ocular applications has been pursued since 
last 10 years. Importantly, due to the micron-sized of MN, damage to the tissue and 
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discomfort/pain can be significantly minimized and allow précised localisation of 
formulation, compared to conventional needles.  
In treating anterior segment diseases, the major advantage that MNs hold when 
compared to traditional topical eye drops is to avoid the major barriers to topical 
ophthalmic drug delivery, e.g. tear fluid and corneal epithelium. Furthermore, micron-
sized tips allow highly localized delivery of drugs compared to traditional topical eye 
drops. Since the drug is directly delivered to the targeted site, dosage requirement can 
be minimized with enhanced bioavailability. For example, a 45-fold increase in 
pilocarpine bioavailability was noted when compared to topical application to the eye 
[49] and a dose of just 4.4 µg of bevacizumab via coated MNs was required, when 
compared to 52,500 µg delivered via eye drops [60]. This indicates significant 
benefits to the treatment of ocular conditions using MNs, with the added advantage of 
being minimal tissue damage. Importantly, decreasing the dosage amount will be 
significant cost savings for some expensive medicines, such as anti-VEGF drug 
ranibizumab, which has been indicated for topical application for patients suffering 
from CNZ. Likewise delivery of other anti-VEGFs and gene therapy could save 
treatment costs, and less dosage can reduce side effects. Furthermore, injecting 
significantly small volumes (<10 µL) within thin tissues, such as in cornea, using 
MNs is highly feasible than conventional needles. Tissue damage and recovery will 
be faster following MN application when compared to hypodermic needles, which in 
turn will reduce chances of unwanted infections. Therefore, MNs can provide distinct 
advantages over topical, subconjunctival and other modes of anterior segment drug 
delivery. 
For posterior segment delivery, MNs could offer potential advantages too. 
Importantly, patients suffering from AMD, DME, retinal vascular occlusions and 
other retinal disorders require frequent IVT of anti-VEGF agents or corticosteroids for 
long-term. Despite encouraging outcomes in improving the vision, the frequent use of 
highly-invasive IVTs has been challenging due to a number of devastating side effects 
and poor patient compliance. Although the risk of losing vision is more frightening, 
the anxiety and fear that patients commonly have during hypodermic needled-based 
IVTs is high. Using significantly shorter MNs can overcome this issue, as 
demonstrated by a number of studies above.  
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Periocular injections using conventional needles could overcome side effects due to 
IVTs. However, due to limited space and very thin tissues (i.e. sclera, SCS), precise 
injections of drug formulations within the tissues is highly impossible and technically 
challenging. Therefore, surgical intervention has been employed to administer drug 
formulations/devices within the tissue [77-79]. But surgical intervention could only 
add to additional side effects and costs. A number of studies have demonstrated that 
the posterior segment drug delivery is achievable by delivering small amounts of drug 
formulations localised within the ocular tissues such as sclera and SCS using MNs. 
And, due to the shorter length of the MNs, no damage to sensitive tissues such as 
retina was noticed.    
To date, very little work has been done on MN-based ocular drug delivery compared 
to transdermal drug delivery; therefore further research is essential to realize the 
benefits of MNs fully. For example, no data has been reported concerning desired MN 
injection forces to the eye that are regarded as safe, since eye cannot tolerate high 
forces due to rise in IOP. Matthew et al 2014 [83] as showed that the force needed to 
insert the hypodermic needle into various areas of the eye wall varies significantly. 
The required force to insert a needle through the anterior sclera, adjacent to the limbus, 
and posterior sclera, adjacent to the optic nerve, was the greatest – measuring around 
1.0 N. However, the force required to penetrate the central cornea was significantly 
lower than all other areas i.e. around 0.5 N except the midline sclera, which requires 
0.7 N. Therefore, it is important to understand the desired forces of injection, where 
the MN design should allow easy insertion and produce minimal discomfort. While 
various designs of MN have been researched for transdermal applications, further 
studies are necessary to thoroughly evaluate the design constraints that could possibly 
hinder MNs performance and efficacy. For example, in terms of the stainless steel 
solid coated MN, the results showed that MN improved fluorescein ocular delivery 
remarkably and the drug in the coating layer was dissolved rapidly within 20 seconds. 
However, only 69% of the applied dose was delivered. The rest of the fluorescein 
either remained adherent to the MN, which was likely due to the incomplete MN 
insertion into the tissue; or may have deposited on the sclera surface [49]. Thus 
highlighting the issues of dosing accuracy and reproducibility. Therefore, special 
attention should be paid for the insertion time, insertion depth, MN design and 
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method of application, as these factors are interrelated for effective MN penetration 
and thereby performance.  
Contrary to the solid silicon MNs, hollow glass MNs are intrinsically brittle and can 
be broken off accidently which can be a cause of concern. Moreover, it has been 
demonstrated that the hollow MN cannot deliver drug solution without retraction of 
MN from the sclera at a predetermined rate (e.g. 60 µm increments every 3 min) and 
to a certain critical distance (around 300 µm). Infusion of drug formulation through 
the hollow MN also requires certain pressure, which is dependent upon viscosity and 
geometric properties of the MN and viscoelastic properties of the ocular tissue. 
Uncontrolled retraction from the sclera could lead complete removal of the MN and 
leakage of the drug onto the sclera surface affecting the amount of drug delivered into 
the sclera. Thus, special insertion devices and infusion system are required so as to 
enable MN-based injections in a controlled manner. On the other hand, use of tissue 
solubilising enzymes (hyaluronidase) can aid the creation of additional space – to 
accommodate the drug formulation at the target location, but both short-term and 
long-term effects of tissue integrity must be taken into considered.  
Unlike steel or glass MNs, biocompatible and biodegradable polymeric materials can 
be used in fabrication of MNs. Polymeric MNs will have the advantage of either 
being completely soluble within the ocular tissue or remain as a depot for long-term 
drug delivery. And, due to the same reason, the disposable of polymeric MNs will be 
less of an issue unlike metal/glass MNs, that will have to perhaps follow similar 
guidelines to that of hypodermic needles.  
Other factors to consider are MNs sterility and mechanical properties. For example, it 
could be easy and cost-effective to have MNs, that are made form steal or glass, to 
sterilise in similar fashion to that of hypodermic needles. However, polymeric MNs 
needs special considerations due to their stability issues to heat and other forms of 
sterilisation; therefore, may need sterile manufacturing. MNs mechanical strength is 
also a key for its effective application – e.g. metal or glass MNs can withstand higher 
forces of application than soluble or polymeric-based MNs. Therefore, it is important 
to consider factors such as type and design of MNs, type of ocular tissues and forces 
required, so as to enable us to develop MNs of desired qualities. Application of MNs 
to the eye is another challenge to be addressed, although it is not as straight forward 
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as it would be for transdermal application. We have discussed a range of MN 
applicator designs previously [84]; likewise appropriate MN applicator for the eye 
should de designed to allow precise injections within a given ocular tissue.  
Although at its early stage, MNs have so far demonstrated a minimally-invasive 
means of localised drug delivery to the eye. However, further research is needed to 
address some of the key challenges. For example, in a recent Phase 1 study it was 
found that a hollow MN injection into SCS was more painful than IVT, presumably 
because of distension caused by the volume of drug injected [85]. Therefore, 
optimization of MN designs, injection volumes, method of injection/retraction, forces 
of injection, pressure of infusion and tissue damage needs to be thoroughly 
investigated. Moreover, MNs can be potentially integrated with sustained drug 
delivery formulations such as nano-/micro-particles, in situ forming injectable 
implants and drug suspension/solution, so as to allow targeted delivery of the 
formulation within the desired ocular tissue to enable long-term drug delivery. 
Finally, MNs has the potential to revolutionise ocular drug delivery, as it achieved 
with transdermal drug delivery. However, this will be highly depended upon the 
translation of its benefits from lab to the clinic, since to date only one clinical trial is 
ongoing in this area.   
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Table 1. Summary of routes of ocular drug delivery. Adapted from [44].  
 
Route Benefits Challenges 
Topical Patient compliance, self-
administration, non-invasive 
Tear dilution and turnover, 
corneal barrier, efflux 
pumps, <5% bioavailability 
Oral/systemic Patient compliance, non-invasive Blood-aqueous barrier, 
blood-retinal barrier, high 
dosing causes toxicity, <2% 
bioavailability 
Intravitreal Direct delivery to vitreous and 
retina, sustained drug levels, 
evades blood-retina barrier 
Retinal detachment, 
haemorrhage, cataract, 
endophtalmitis, patient 
incompliance 
Intracameral Higher drug levels in anterior 
chamber, eliminates use of drops, 
reduces corneal and systemic side 
effects seen with topical steroid 
therapy 
Toxic anterior segment 
syndrome, toxic endothelial 
cell destruction syndrome 
Subconjunctival Anterior and posterior delivery, 
potential for depot formulations 
Conjunctival and corneal 
circulation 
Subtenon High vitreal drug levels, relatively 
non-invasive, fewer complications 
than intravitreal 
Retinal pigmented 
epithelium, chemosis, 
subconjunctival 
haemorrhage 
Retrobulbar High local doses of anaesthetics, 
more effective than peribulbar, 
minimal effect on intraocular 
pressure 
Retrobulbar haemorrhage, 
glober perforation, 
respiratory arrest 
Posterior 
juxtascleral 
Safe for depot delivery, sustained 
drug levels for up to 6 months to 
macula, avoids risk of 
endophtalmitis and intraocular 
damage 
Surgery, retinal pigmented 
epithelium acts as barrier. 
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Figure 1. Schematic representation showing various routes of ocular drug delivery.  
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Figure 2. Digital photograph showing intrastromal injection of fluconazole using hypodermic needle to 
treat fungal keratitis. Adapted from [50]. 
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Figure 3. Schematic representation of different modes of MN application. (a) Poke and patch 
– application and removal of solid MNs and followed by application of drug-loaded reservoir. 
(b) Coat and poke – application of coated MNs for deposition of drug-containing layer in the 
skin. (c) Application of dissolving MNs (made of polymer or sugar) for delivery of 
incorporated drug into the skin. (d) Injection of drug formulation using hollow MNs. (e) 
Application of swelling MNs for drug delivery through the hydrogel matrix from a drug-
loaded reservoir [66].  
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(a) 
  
(b) 
 
(c) 
                                   (d)  
Figure 4. (a) Microscopic image of a single solid stainless-steel MN used for intrascleral and 
intracorneal administration shown next to a US penny. The inset shows magnified view of the MN, 
which is 500 µm in length and 45° in tip angle [49]. (b) Representative glass-based HMN with a bevel 
tip angle of 25° [68] (c) Image showing 1000 nm particles distribution into the SCS of human eye, ex 
vivo. The inset represents a magnified view of the HMN insertion site. Scale bar is 500 µm [69]. (d) 
Shows a photograph of; (i) spring-loaded MN pen; (ii) MN guiding structure at the end of MN pen and 
(iii) transfer molded MN structure on the tip end of MN pen. Scale bar is 100 µm [73]. 
a. Reproduced with permission from [49].  
b. Reproduced with permission from [68].  
c. Reproduced with permission from [69].  
d. Reproduced with permission from [73].  
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(a) (b) 
 (c) 
Figure 5. (a) Shows digital image of a biodegradable scleral plug containing that is 5 mm in length and 
1 mm in diameter [76]. (b) Image of intrascleral implant, in rabbit eye, at the site of surgical 
administration one week after the implantation. The inset shows the biodegradable one-side coated 
triamcinolone acetonide intrascleral implant with 1 mm in thickness and 3 mm in diameter [79]. (c) 
Optical coherence tomography images showing 30 G HMN injection of 50 µl fluorescein sodium-
loaded poloxamer gel injected into equatorial sclera to a depth of 400 µm at (a) 0, and (b) 1 and (c) 2 h 
after injections, where the arrow indicates empty space in sclera created following HMN application 
and its subsequent closure over time [67].  
a. Reproduced with permission from [76].  
b. Reproduced with permission from [79].  
c. Reproduced with permission from [67].  
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